SecBot SecBot

APLS

Apellis Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001492422 Biotech & Drug Discovery
No price
Median target
$41.00
range $40.00–41.00
Short interest
10.75M
−24.5%
Days to cover
3.1
at average volume
Insider net
$0
no open-market trades · since May 14
New fund stakes
0
Q2 2026 13F · 49 exits
Filing reports
5
analyzed by SecBot
SecBot read BULLISH 5 reports · latest
Balance 0 bearish · 1 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 5/5

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since May 14. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q2 2026: 0 added (0 new), 49 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.353 → −$0.318 over 90 days. 0 up, 2 down in 30 days.

  • Short sellersCOVERING

    Short interest −24.5% to 10.75M shares. 3.1 days to cover.

Who's buying

13F· Q2 2026
0
new positions
49
exits

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Oct 2024
Recent actions
DateFirmActionRating
Oct 16, 2024Scotiabank
INITIATE
INITIATESector Perform
Oct 16, 2024William Blair
INITIATE
INITIATEOutperform
Sep 24, 2024Wells Fargo
MAINTAIN
MAINTAINEqual-Weight
Sep 23, 2024Baird
MAINTAIN
MAINTAINOutperform
Sep 20, 2024Mizuho
MAINTAIN
MAINTAINNeutral
Sep 20, 2024Needham
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · since May 14
DateInsiderTypeValue
May 14, 2026
Watson David O.
General Counsel
May 14, 2026
TO ISSUER11,874 sh
May 14, 2026
Watson David O.
General Counsel
May 14, 2026
TO ISSUER6,001 sh
May 14, 2026
Watson David O.
General Counsel
May 14, 2026
TO ISSUER7,363 sh
May 14, 2026
Watson David O.
General Counsel
May 14, 2026
TO ISSUER14,000 sh
May 14, 2026
Watson David O.
General Counsel
May 14, 2026
TO ISSUER50,974 sh
May 14, 2026
Watson David O.
General Counsel
May 14, 2026
TO ISSUER38,250 sh
May 14, 2026
Watson David O.
General Counsel
May 14, 2026
TO ISSUER45,000 sh
May 14, 2026
Watson David O.
General Counsel
May 14, 2026
TO ISSUER37,708 sh

Earnings setup

Estimates
−$0.32
EPS estimate, this quarter
+10%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.32-$0.49–-$0.16+3.5%$209.9M
Next Q-$0.28-$0.60–-$0.10-6.2%$219.2M
Next FY-$0.31-$2.02–$0.68-28.7%$1.0B
Current FY-$1.17-$2.19–-$0.38-4.1%$924.9M

Short side

FINRA· Apr 30, 2026
10,752,810
shares short
-24.5%
vs prior settlement
3.1
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Oct 20, 2026 Event
Lyday et al v. Apellis Pharmaceuticals Inc
Court ruling (txnd), Docket: 3:24-cv-02044
Aug 21, 2026 Event
Empaveli
WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA EMPAVELI, a complement inhibitor, increa
Jul 29, 2026 Earnings calendar
APLS Q2 2026 Earnings Scheduled, 2026-07-29
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC · EXIT
0 shares ($0.00)
Jun 30, 2026 Inst.
JPMORGAN CHASE & CO · EXIT
0 shares ($0.00)
May 26, 2026 SEC
Apellis Pharmaceuticals filed Form 15-12G to terminate its SEC registration and suspend reporting obligations…
15-12G · Impact 6/10
May 14, 2026 SEC
Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common stock from listing and registration, effective…
25-NSE · Impact 2/10
May 14, 2026 SEC
Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, through a tender offer and subsequent…
8-K · Impact 8/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

5 filings · 1 bullish · 0 bearish · 1 mixed · 3 neutral
All APLS filing & press-release reports (5)